Making real world evidence fit for purposeAlthough real world evidence (RWE) is a hot topic in pharma right now, many still question whether it Share XMaking real world evidence fit for purposehttps://pharmaphorum.com/views-analysis-market-access/making-real-world-evidence-fit-for-purpose/
Future prospects for an Innovative Medicines Fund for EnglandOn the 12 December 2019, the UK general public voted for a further five years of Conservative government. Share XFuture prospects for an Innovative Medicines Fund for Englandhttps://pharmaphorum.com/views-analysis-market-access/future-prospects-for-an-innovative-medicines-fund-for-england/
Nine pharma trends for 2020Sarah Rickwood looks back at how pharma changed over the last decade and what this might mean for Share XNine pharma trends for 2020https://pharmaphorum.com/views-analysis-digital/nine-pharma-trends-for-2020/
The 4 biggest pharma market access stories of 2019What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive Share XThe 4 biggest pharma market access stories of 2019https://pharmaphorum.com/views-analysis-market-access/the-4-biggest-pharma-market-access-stories-of-2019/
An alternative set of metrics for the UK’s pricing and access dealLeela Barham takes a look at alternative ways pharma and the UK government could measure progress for the Share XAn alternative set of metrics for the UK’s pricing and access dealhttps://pharmaphorum.com/views-and-analysis/an-alternative-set-of-metrics-for-the-uks-pricing-and-access-deal/
15 pharma trends for 2020Real world evidence, patient centricity and new digital experiences are among the top 15 trends set to change Share X15 pharma trends for 2020https://pharmaphorum.com/views-analysis-digital/15-pharma-trends-for-2020/
How does prevalence affect pricing of rare disease drugs?New research from CRA looks at the relationship between rarity of a disease and the price countries are Share XHow does prevalence affect pricing of rare disease drugs?https://pharmaphorum.com/views-analysis-market-access/prevalence-pricing-rare-disease-drugs/
Nine for 2019: how did we do on our predictions, and what does this mean for 2020?Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead. At Share XNine for 2019: how did we do on our predictions, and what does this mean for 2020?https://pharmaphorum.com/views-and-analysis/nine-for-2019-2020/
Q&A: Zulf Masters on emerging marketsUK-based Masters Speciality Pharma focuses on supplying medicines to developing countries where access to treatments is limited – Share XQ&A: Zulf Masters on emerging marketshttps://pharmaphorum.com/views-analysis-market-access/qa-zulf-masters-on-emerging-markets/
